Small-cap IPOs are coming back, and fast. After years of stalled deals and weak listings, the first quarter of 2025 has already produced 56 new IPOs, an 80 percent increase compared to the same period last year. That is a meaningful shift after two years of companies staying private, waiting for market conditions to improve.
This is not a one-off blip. Companies that held back during the post-pandemic slowdown are now stepping forward. And investors are responding.
From Drought to Momentum
In 2021, IPOs were booming with over 1,000 listings as stimulus money flooded the market. By 2024, that number had dropped to barely 130. This year's activity points to something more than just pent-up supply. It suggests the window is reopening.
The Russell 2000 is up nearly 14 percent year to date, outperforming the S&P 500, which has gained just over 10 percent. Institutional capital is beginning to rotate back into smaller, high-growth names.
What Is Fueling the Change
With the Federal Reserve stepping back from its rate hike cycle, financing conditions are finally less restrictive. That makes it easier for startups to pursue public listings. Private companies that were once hesitant are now looking to move while investor sentiment is improving.
Private equity and venture capital firms are also pushing the trend. Many had been stuck holding investments longer than expected. Now, with market interest returning, they are aiming to exit at valuations that make sense again.
Sectors Leading the Wave
Technology remains the anchor of the IPO rebound. Companies focused on AI infrastructure, cybersecurity, and digital platforms are drawing significant attention. One of the most closely watched IPOs is CoreWeave, a cloud firm serving the AI ecosystem. If it performs well, it could encourage others to follow.
Fintech is also making a comeback. Swedish firm Klarna is rumored to be preparing a U.S. listing in 2025. After years of losses and regulatory pressure, the space is showing signs of life as capital becomes more available.
Biotech is gaining momentum too. Many early-stage biotech companies rely heavily on IPO funding to fuel research. With sentiment improving and risk tolerance returning, several are preparing to list after a long wait on the sidelines.
Risks That Still Matter
Despite the momentum, IPOs at this stage come with risks. The biggest is valuation. Many of these companies are still early in their development. Revenue forecasts may be ambitious, but profitability often remains far off. If results do not meet projections, early investors could see steep losses.
Liquidity is another concern. Small-cap IPOs typically trade at lower volumes. That makes them more volatile and sensitive to short-term sentiment shifts. In 2021, IPOs gained an average of 41 percent on their first day of trading. In 2022, that number dropped to just six percent. The business models didn't change. Market psychology did.
Investors also need to watch for lock-up periods. These prevent early investors and insiders from selling shares for several months after the IPO. When those expire, many look to cash out, which can trigger a sharp drop in share price. That pattern caught a lot of retail investors off guard during the last IPO cycle.
It is not 2021. No one should expect overnight 10x returns. But for investors who are prepared to research the fundamentals, assess risk, and move selectively, this environment offers real opportunity.
Some of these companies will become industry leaders. Others will fade. The difference will come down to who does the homework and who gets caught chasing the next big thing without understanding what they are buying.
Disclaimer
We are not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authorities. Further, our owners, employees, agents are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authorities.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of our websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Disclaimer: Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and our partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing herein constitutes a recommendation respecting the particular security illustrated.